The first two authors contributed equally two this work.
Resveratrol enhances p53 acetylation and apoptosis in prostate cancer by inhibiting MTA1/NuRD complex
Article first published online: 6 OCT 2009
Copyright © 2009 UICC
International Journal of Cancer
Volume 126, Issue 7, pages 1538–1548, 1 April 2010
How to Cite
Kai, L., Samuel, S. K. and Levenson, A. S. (2010), Resveratrol enhances p53 acetylation and apoptosis in prostate cancer by inhibiting MTA1/NuRD complex. Int. J. Cancer, 126: 1538–1548. doi: 10.1002/ijc.24928
- Issue published online: 28 JAN 2010
- Article first published online: 6 OCT 2009
- Manuscript Accepted: 10 SEP 2009
- Manuscript Received: 7 JUL 2009
- 1Lifestyle recommendations to prevent prostate cancer, part II: time to redirect our attention? Urol Clin North Am 2004; 31: 301–11., .
- 2Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res 2004; 24: 2783–840., , , , , .
- 3Chemoprevention of prostate cancer through dietary agents: progress and promise. Cancer Epidemiol Biomarkers Prev 2007; 16: 2193–203., , , .
- 4Resveratrol as an antiproliferative agent for cancer. In: AggarwalBB, ShishodiaS, eds. Resveratrol in health and disease. Boca Raton, London: Taylor & Fransic Group, 2004. 439–64..
- 5Resveratrol suppresses the angiogenesis and tumor growth of gliomas in rats. Clin Cancer Res 2004; 10: 2190–202., , , , , , , .
- 6Suppression of angiogenesis, tumor growth, and wound healing by resveratrol, a natural compound in red wine and grapes. FASEB J 2001; 15: 1798–800., , .
- 7Resveratrol isolated from Polygonum cuspidatum root prevents tumor growth and metastasis to lung and tumor-induced neovascularization in Lewis lung carcinoma-bearing mice. J Nutr 2001; 131: 1844–9., .
- 8Resveratrol suppresses hepatoma cell invasion independently of its anti-proliferative action. Cancer Lett 2001; 167: 151–6., , .
- 9Suppression of 7,12-dimethylbenz(a)anthracene-induced mammary carcinogenesis in rats by resveratrol: role of nuclear factor-kappaB, cyclooxygenase 2, and matrix metalloprotease 9. Cancer Res 2002; 62: 4945–54., , .
- 10Deactivation of cultured human liver myofibroblasts by trans-resveratrol, a grapevine-derived polyphenol. Hepatology 2000; 31: 922–31., , , , , , .
- 11A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature 1994; 370: 61–5., , , , , , .
- 12Resveratrol down-regulates the androgen receptor at the post-translational level in prostate cancer cells. J Nutr Sci Vitamin 2007; 53: 556–60., , , , , .
- 13Resveratrol suppresses prostate cancer progression in transgenic mice. Carcinogenesis 2007; 28: 1946–53., , , , , .
- 14Resveratrol increases nitric oxide synthase, induces accumulation of p53 and p21(WAF1/CIP1), and suppresses cultured bovine pulmonary artery endothelial cell proliferation by perturbing progression through S and G2. Cancer Res 1999; 59: 2596–601., , , .
- 15Resveratrol promotes differentiation and induces Fas-independent apoptosis of human medulloblastoma cells. Neurosci Lett 2003; 351: 83–6., , , , , .
- 16Resveratrol-induced apoptosis in MCF-7 human breast cancer cells involves a caspase-independent mechanism with downregulation of Bcl-2 and NF-kappaB. Int J Cancer 2005; 115: 74–84., , , , , , .
- 17Mechanisms involved in resveratrol-induced apoptosis and cell cycle arrest in prostate cancer-derived cell lines. J Androl 2007; 28: 282–93., , , , .
- 18Resveratrol induces prostate cancer cell entry into s phase and inhibits DNA synthesis. Cancer Res 2002; 62: 2488–92., , , , , .
- 19Chemopreventive agent resveratrol, a natural product derived from grapes, triggers CD95 signaling-dependent apoptosis in human tumor cells. Blood 1998; 92: 996–1002., , , .
- 20Resveratrol modulates the phosphoinositide 3-kinase pathway through an estrogen receptor alpha-dependent mechanism: relevance in cell proliferation. Int J Cancer 2004; 109: 167–73., , .
- 21Identification of proteins within the nuclear factor-kappa B transcriptional complex including estrogen receptor-alpha. Am J Obst Gynecol 2007; 196: 394 e1–11; discussion e11-e13., , , , .
- 22Non-genomic action of resveratrol on androgen and oestrogen receptors in prostate cancer: modulation of the phosphoinositide 3-kinase pathway. Br J Cancer 2007; 96: 1595–604., , , , .
- 23Inhibition of cancer growth by resveratrol is related to its low bioavailability. Free Radical Biol Med 2002; 33: 387–98., , , , , , .
- 24Metabolism and disposition of resveratrol in rats: extent of absorption, glucuronidation, and enterohepatic recirculation evidenced by a linked-rat model. J Pharm Exp Ther 2002; 302: 369–73., , , , , .
- 25Take a break–resveratrol in action on DNA. Carcinogenesis 2008; 29: 321–32., .
- 26Epigenetic modulation and cancer: effect of metabolic syndrome? Am J Clin Nutr 2007; 86: s872–s877., .
- 27Epigenetic changes in prostate cancer: implication for diagnosis and treatment. J Nat Cancer Inst 2005; 97: 103–15., , .
- 28HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention. Oncogene 2007; 26: 5310–18., .
- 29Role of histone modification in chromatin dynamics. J Biochem 2007; 141: 609–14..
- 30Histone deacetylase inhibitors in cancer therapy: new compounds and clinical update of benzamide-type agents. Curr Topics Med Chem 2008; 8: 841–58., , .
- 31Targeting epigenetic abnormalities with histone deacetylase inhibitors. Cancer 2006; 107: 832–40., , .
- 32Clinical development of histone deacetylase inhibitors as anticancer agents. Ann Rev Pharm Toxicol 2005; 45: 495–528., , , , , .
- 33Discovery and development of SAHA as an anticancer agent. Oncogene 2007; 26: 1351–6..
- 34Dietary histone deacetylase inhibitors: from cells to mice to man. Sem Cancer Biol 2007; 17: 363–9., .
- 35Mechanism of human SIRT1 activation by resveratrol. J Biol Chem 2005; 280: 17187–95., , .
- 36Acetylation of Sirt2 by p300 attenuates its deacetylase activity. Biochem Biophys Res Commun 2008; 375: 576–80., , , , , , , .
- 37Oestrogen inhibits resveratrol-induced post-translational modification of p53 and apoptosis in breast cancer cells. Br J Cancer 2004; 91: 178–85., , , , , .
- 38Differential expression of genes induced by resveratrol in LNCaP cells: P53-mediated molecular targets. Int J Cancer 2003; 104: 204–12., , , .
- 39Resveratrol induced serine phosphorylation of p53 causes apoptosis in a mutant p53 prostate cancer cell line. J Urol 2002; 168: 748–55., , , , , , .
- 40Genome-wide profiling of histone h3 lysine 4 and lysine 27 trimethylation reveals an epigenetic signature in prostate carcinogenesis. PloS One 2009; 4: e4687., , , , , , , , , , , , et al.
- 41A novel candidate metastasis-associated gene, mta1, differentially expressed in highly metastatic mammary adenocarcinoma cell lines. cDNA cloning, expression, and protein analyses. J Biol Chem 1994; 269: 22958–63., , .
- 42NURD, a novel complex with both ATP-dependent chromatin-remodeling and histone deacetylase activities. Mol Cell 1998; 2: 851–61., , , , , .
- 43Metastasis-associated protein 1 inhibits p53-induced apoptosis. Oncol Rep 2007; 18: 1311–14., , .
- 44Breast tumors that overexpress nuclear metastasis-associated 1 (MTA1) protein have high recurrence risks but enhanced responses to systemic therapies. Breast Cancer Res Treat 2006; 95: 7–12., , , , , , , .
- 45The role of the MTA family and their encoded proteins in human cancers: molecular functions and clinical implications. Clin Exp Metastasis 2009; 26: 215–27., .
- 46Overexpression of the MTA1 gene in gastrointestinal carcinomas: correlation with invasion and metastasis. Int J Cancer 1997; 74: 459–63., , , , , , , .
- 47Overexpression of metastasis-associated MTA1 mRNA in invasive oesophageal carcinomas. Br J Cancer 1999; 79: 1723–6., , , , .
- 48Expression of MTA1, a metastasis-associated gene with histone deacetylase activity in pancreatic cancer. Int J Oncol 2000; 16: 1211–14., , , .
- 49Expression of the MTA1 mRNA in advanced lung cancer. Lung Cancer 2002; 35: 149–54., , , , , , , , , .
- 50The role of metastasis-associated protein 1 in prostate cancer progression. Cancer Res 2004; 64: 825–9., , , , , , , , , , , , et al.
- 51Resveratrol acts as an estrogen receptor (ER) agonist in breast cancer cells stably transfected with ER alpha. Int J Cancer 2003; 104: 587–96., , , , , , , .
- 52Analysis of relative gene expression data using real-time quantitative PCR and the 2(−ΔΔC(T)) Method Methods 2001; 25: 402–8., .
- 53p53 is preferentially recruited to the promoters of growth arrest genes p21 and GADD45 during replicative senescence of normal human fibroblasts. Cancer Res 2006; 66: 8356–60., .
- 54Metastasis-associated protein 1 enhances stability of hypoxia-inducible factor-1alpha protein by recruiting histone deacetylase 1. EMBO J 2006; 25: 1231–41., , .
- 55Targeting the p53-MDM2 interaction to treat cancer. Br J Cancer 2004; 91: 1415–9., .
- 56Acetylation of p53 activates transcription through recruitment of coactivators/histone acetyltransferases. Mol Cell 2001; 8: 1243–54., , , , , , .
- 57FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 2007; 12: 1247–52., , , , .
- 58Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. Proc Natl Acad Sci USA 2004; 101: 1241–6., , , , .
- 59Predicting the physiological relevance of in vitro cancer preventive activities of phytochemicals. Acta Pharm Sinica 2007; 28: 1274–304., , , , , , , .
- 60MTA1 overexpression correlates significantly with tumor grade and angiogenesis in human breast cancers. Cancer Sci 2006; 97: 374–9., , , , .
- 61Targeting the ubiquitin system in cancer therapy. Nature 2009; 458: 438–44., .
- 62Transcriptional repression of oestrogen receptor by metastasis-associated protein 1 corepressor. Nat Cell Biol 2001; 3: 30–7., , , , , , , .
- 63Resveratrol acts as a mixed agonist/antagonist for estrogen receptors α and β. Endocrinology 2000; 141: 3657–67., , , .
- 64Resveratrol, a polyphenolic compound found in grapes and wine, is an agonist for the estrogen receptor. Proc Natl Acad Sci USA 1997; 94: 14138–43., , , .
- 65Raloxifene, a mixed estrogen agonist/antagonist, induces apoptosis in androgen-independent human prostate cancer cell lines. Cancer Res 2002; 62: 5365–9., , , , , , , , .
- 66Array-based analysis of the effects of trichostatin A and CG-1521 on cell cycle and cell death in LNCaP prostate cancer cells. Mol Cancer Ther 2008; 7: 1931–9., , .
- 67Site-specific acetylation of p53 directs selective transcription complex assembly. J Biol Chem 2007; 282: 4765–71., .
- 68Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 1999; 401: 188–93., , , , , , , .
- 69Drug insight: Histone deacetylase inhibitors–development of the new targeted anticancer agent suberoylanilide hydroxamic acid. Nat Clin Pract Oncol 2005; 2: 150–7., .
- 70Suberoylanilide hydroxamic acid as a potential therapeutic agent for human breast cancer treatment. Mol Med 2000; 6: 849–66., .
- 71Chemopreventive potential of resveratrol in mouse skin tumors through regulation of mitochondrial and PI3K/AKT signaling pathways. Pharm Res 2009; 26: 211–17., , , , .
- 72Inhibitory effect of epidermal growth factor on resveratrol-induced apoptosis in prostate cancer cells is mediated by protein kinase C-α. Mol Cancer Ther 2004; 3: 1355–64., , , , , , , , , .
- 73Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res 2000; 60: 5165–70., , , , , , , , , .
- 74Histone deacetylase inhibitors differentially mediate apoptosis in prostate cancer cells. Prostate 2005; 62: 299–306., .
- 75Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? Cancer Cell 2003; 4: 13–18., .
- 76Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (Vorinostat. SAHA) profoundly inhibits the growth of human pancreatic cancer cells. Int J Cancer 2007; 121: 656–65., , , , , , , , , .
- 77Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci USA 2000; 97: 10014–9., , , .
- 78Complementation of two mutant p53: implications for loss of heterozygosity in cancer. FEBS Lett 2005; 579: 2231–5., , .